anti-miR-221 + anti-miR-222

**anti-miR-221 + anti-miR-222** is a combination of synthetic antisense oligonucleotides designed to inhibit the oncogenic microRNAs miR-221 and miR-222, which are frequently upregulated in various cancers and contribute to chemotherapy resistance, proliferation, and survival. By binding to and sequestering these miRNAs, the inhibitors upregulate key targets such as p27Kip1, PTEN, SOCS1, p53, and PUMA, leading to cell cycle arrest, apoptosis induction, and enhanced sensitivity to chemotherapeutics like cisplatin. Preclinical studies have demonstrated synergistic antitumor effects in models of triple-negative breast cancer (TNBC), multiple myeloma (MM), prostate cancer, and hepatocellular carcinoma, including reduced tumor growth in xenograft mice via local or systemic delivery, often with cholesterol modification for improved stability and targeting.

Other names

miR-221/222 inhibitors